(AZN) AstraZeneca - Ratings and Ratios
Oncology, Cardiovascular, Respiratory, Rare-Disease, Vaccines
AZN EPS (Earnings per Share)
AZN Revenue
Description: AZN AstraZeneca September 24, 2025
AstraZeneca PLC (NASDAQ: AZN) is a globally diversified biopharmaceutical firm that discovers, develops, manufactures and commercializes prescription medicines across oncology, cardiovascular-renal-metabolism, respiratory-immunology, vaccines, and rare-disease segments. Its product slate includes high-growth oncology agents such as Tagrisso, Imfinzi and Lynparza, as well as leading cardiovascular drugs like Farxiga and Brilinta, and respiratory inhalers such as Symbicort and Breztri.
The company reaches physicians through a mix of direct sales forces and third-party distributors in the United Kingdom, United States, Europe and Asia. Recent strategic moves include a multimodal AI-driven oncology model with Tempus, a quantum-accelerated chemistry partnership with IonQ, and a joint discovery program with CSPC Pharmaceutical targeting oral small-molecule candidates. These collaborations are intended to shorten R&D cycles and expand AZN’s pipeline breadth.
Financially, AstraZeneca reported FY 2023 revenue of $44.4 billion, with oncology contributing roughly 38 % of sales and delivering a 12 % YoY growth rate. R&D expenditure remained steady at $7.1 billion (≈16 % of revenue), reflecting a commitment to pipeline renewal. The stock trades at a forward-PE of about 15×, below the sector median of ~18×, and offers a dividend yield near 2.5 %.
Key sector drivers that could materially affect AZN’s outlook include the aging global population (projected to increase the over-65 demographic by 30 % by 2035), sustained US healthcare spending growth (~5 % CAGR), and accelerating adoption of AI-enabled drug discovery, which may improve hit-to-clinic conversion rates across the industry.
For a deeper quantitative assessment of AZN’s valuation metrics and forward cash-flow projections, the ValueRay platform offers a transparent, data-driven model worth exploring.
AZN Stock Overview
| Market Cap in USD | 258,635m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1993-05-12 |
AZN Stock Ratings
| Growth Rating | 70.7% |
| Fundamental | 77.2% |
| Dividend Rating | 40.5% |
| Return 12m vs S&P 500 | -2.61% |
| Analyst Rating | 4.42 of 5 |
AZN Dividends
| Dividend Yield 12m | 1.86% |
| Yield on Cost 5y | 3.40% |
| Annual Growth 5y | 1.48% |
| Payout Consistency | 96.4% |
| Payout Ratio | 37.2% |
AZN Growth Ratios
| Growth Correlation 3m | 65.6% |
| Growth Correlation 12m | 77.4% |
| Growth Correlation 5y | 88.4% |
| CAGR 5y | 13.02% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.47 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.31 |
| Sharpe Ratio 12m | 0.55 |
| Alpha | 5.25 |
| Beta | 0.165 |
| Volatility | 21.51% |
| Current Volume | 2977.7k |
| Average Volume 20d | 4902.2k |
| Stop Loss | 79.9 (-3%) |
| Signal | 0.15 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (8.29b TTM) > 0 and > 6% of Revenue (6% = 3.39b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 1.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -8.14% (prev -6.46%; Δ -1.68pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 13.39b > Net Income 8.29b (YES >=105%, WARN >=100%) |
| Net Debt (25.78b) to EBITDA (18.57b) ratio: 1.39 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (3.12b) change vs 12m ago -0.06% (target <= -2.0% for YES) |
| Gross Margin 81.40% (prev 82.08%; Δ -0.69pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.13% (prev 47.09%; Δ 5.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.01 (EBITDA TTM 18.57b / Interest Expense TTM 1.67b) >= 6 (WARN >= 3) |
Altman Z'' 0.81
| (A) -0.04 = (Total Current Assets 28.94b - Total Current Liabilities 33.54b) / Total Assets 112.42b |
| (B) 0.06 = Retained Earnings (Balance) 7.02b / Total Assets 112.42b |
| (C) 0.11 = EBIT TTM 11.74b / Avg Total Assets 108.38b |
| (D) 0.14 = Book Value of Equity 9.48b / Total Liabilities 67.61b |
| Total Rating: 0.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 77.15
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 3.07% = 1.53 |
| 3. FCF Margin 15.44% = 3.86 |
| 4. Debt/Equity 0.73 = 2.24 |
| 5. Debt/Ebitda 1.39 = 1.16 |
| 6. ROIC - WACC (= 6.82)% = 8.52 |
| 7. RoE 19.84% = 1.65 |
| 8. Rev. Trend 94.91% = 7.12 |
| 9. EPS Trend -28.73% = -1.44 |
What is the price of AZN shares?
Over the past week, the price has changed by -1.07%, over one month by +7.40%, over three months by +13.51% and over the past year by +18.23%.
Is AstraZeneca a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AZN is around 86.11 USD . This means that AZN is currently overvalued and has a potential downside of 4.5%.
Is AZN a buy, sell or hold?
- Strong Buy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AZN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 89.8 | 8.9% |
| Analysts Target Price | 89.8 | 8.9% |
| ValueRay Target Price | 93.9 | 13.9% |
AZN Fundamental Data Overview October 27, 2025
P/E Trailing = 31.312
P/E Forward = 16.3132
P/S = 4.5775
P/B = 5.7997
P/EG = 0.9658
Beta = 0.165
Revenue TTM = 56.50b USD
EBIT TTM = 11.74b USD
EBITDA TTM = 18.57b USD
Long Term Debt = 24.71b USD (from longTermDebt, last quarter)
Short Term Debt = 6.85b USD (from shortTermDebt, last quarter)
Debt = 32.84b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 25.78b USD (from netDebt column, last quarter)
Enterprise Value = 284.37b USD (258.64b + Debt 32.84b - CCE 7.11b)
Interest Coverage Ratio = 7.01 (Ebit TTM 11.74b / Interest Expense TTM 1.67b)
FCF Yield = 3.07% (FCF TTM 8.72b / Enterprise Value 284.37b)
FCF Margin = 15.44% (FCF TTM 8.72b / Revenue TTM 56.50b)
Net Margin = 14.68% (Net Income TTM 8.29b / Revenue TTM 56.50b)
Gross Margin = 81.40% ((Revenue TTM 56.50b - Cost of Revenue TTM 10.51b) / Revenue TTM)
Gross Margin QoQ = 82.89% (prev 83.57%)
Tobins Q-Ratio = 2.53 (Enterprise Value 284.37b / Total Assets 112.42b)
Interest Expense / Debt = 1.34% (Interest Expense 439.0m / Debt 32.84b)
Taxrate = 21.71% (679.0m / 3.13b)
NOPAT = 9.19b (EBIT 11.74b * (1 - 21.71%))
Current Ratio = 0.86 (Total Current Assets 28.94b / Total Current Liabilities 33.54b)
Debt / Equity = 0.73 (Debt 32.84b / totalStockholderEquity, last quarter 44.72b)
Debt / EBITDA = 1.39 (Net Debt 25.78b / EBITDA 18.57b)
Debt / FCF = 2.96 (Net Debt 25.78b / FCF TTM 8.72b)
Total Stockholder Equity = 41.82b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.38% (Net Income 8.29b / Total Assets 112.42b)
RoE = 19.84% (Net Income TTM 8.29b / Total Stockholder Equity 41.82b)
RoCE = 17.65% (EBIT 11.74b / Capital Employed (Equity 41.82b + L.T.Debt 24.71b))
RoIC = 12.81% (NOPAT 9.19b / Invested Capital 71.75b)
WACC = 5.99% (E(258.64b)/V(291.47b) * Re(6.62%) + D(32.84b)/V(291.47b) * Rd(1.34%) * (1-Tc(0.22)))
Discount Rate = 6.62% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.06%
[DCF Debug] Terminal Value 80.01% ; FCFE base≈8.02b ; Y1≈9.10b ; Y5≈12.41b
Fair Price DCF = 69.29 (DCF Value 214.85b / Shares Outstanding 3.10b; 5y FCF grow 15.61% → 3.0% )
EPS Correlation: -28.73 | EPS CAGR: -53.22% | SUE: -4.0 | # QB: 0
Revenue Correlation: 94.91 | Revenue CAGR: 10.51% | SUE: 0.94 | # QB: 1
Additional Sources for AZN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle